Bristol-Myers Squibb Stock
Bristol-Myers Squibb Stock
Bristol-Myers Squibb shows a slight decrease today, losing -€0.235 (-0.470%) compared to yesterday.
Our community is currently high on Bristol-Myers Squibb with 13 Buy predictions and 4 Sell predictions.
With a target price of 57 € there is a slightly positive potential of 14.58% for Bristol-Myers Squibb compared to the current price of 49.75 €.
Our community identified positive and negative aspects for Bristol-Myers Squibb stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Bristol-Myers Squibb stock. On the other hand our users think that "Business model" could be a problem in the future.
Pros and Cons of Bristol-Myers Squibb in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Bristol-Myers Squibb vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | -0.470% | -3.271% | -3.532% | 11.812% | 8.475% | -22.150% | -4.981% |
| BioMarin Pharmaceutical Inc. | 0.920% | -3.367% | -10.783% | -7.186% | -8.644% | -49.024% | -28.174% |
| Johnson & Johnson | -0.100% | -3.465% | -3.167% | 52.071% | 15.056% | 35.116% | 50.162% |
| Biogen Inc. | 0.200% | -4.122% | -10.386% | 45.281% | -1.595% | -43.285% | -34.549% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2025-04-26
Bristol Myers Squibb Co. (BMY) has reported its Q2 2025 financial results as of March 31, 2025. The company's current financial position shows a mixed trend with both positive and challenging indicators.
Key Findings: * Revenue decreased to $11.201 billion from $11.865 billion in the same quarter last year * Net profit significantly improved to $2.456 billion compared to a loss of $11.911 billion in Q2 2024 * Cash and cash equivalents increased to $10.875 billion from $9.334 billion as of March 31, 2024
Overall Trend: Mixed, with improving profitability but declining revenue.
Comments
Bristol Myers Squibb (BMY) had its price target lowered by Bank of America Corporation from $68.00 to $67.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BMY provided by MarketBeat
Bristol Myers Squibb (BMY) had its "buy" rating reaffirmed by Guggenheim. They now have a $72.00 price target on the stock.
Show more
Ratings data for BMY provided by MarketBeat
Bristol Myers Squibb (BMY) had its "buy" rating reaffirmed by UBS Group AG.
Show more
Ratings data for BMY provided by MarketBeat